Ascend Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Ascend Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-382,348	Closed	-$19.7M	–	164
2017 Q2	$19.7M	Buy	+382,348	New	+$19.5M	0.92%	37

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ascend Capital's AGIO Position: Q3 2017 in Review

Ascend Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 382,348 shares — an estimated $19.7M sold.

Ascend Capital first reported a position in AGIO in Q2 2017 and held it in 1 quarter. The position peaked at $19.7M in Q2 2017. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

Ascend Capital reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Ascend Capital sold 382,348 Agios Pharmaceuticals shares in Q3 2017, an estimated $19.7M.
Ascend Capital first reported a position in Agios Pharmaceuticals in Q2 2017 and held it in 1 quarter.
Ascend Capital's Agios Pharmaceuticals position peaked at $19.7M in Q2 2017.
171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.